coreen was shown to not be similar and it's function to use you know one of the other piece of evidence that was used  phosphorylation will tell you is that that may be an indication that there is a terrace in case inhibition taking place but it can also be increased phosphatase activity and both experts agreed that you need to understand whether there was increased because there are notes that the difference actually and i cannot in any one the investigators noted that actual difference in hydroxyl may be the precise reason why there's a difference in function so it's a force it's different that included up substantially advances aspect of the takings clause subsequent supreme court cases including the legal case l i n g l vs chevron held that in a takings clause we presume that the current progression of the congress was provided adequate basis and has a lot that's appropriate whereas in the due process that you process case you look at both the government's interest and whether it's a rational it it can be reexamined because that law is no longer right and the supreme court to took pains to correct that in one go days so our position is that alex can be reexamined right supreme court case and the takings clause case can be decided we as i said the constitutional law issue involves both the due process and takings us both of those  insubstantial do something to do process which is rarely granted we understand that it's a basis the basis is whether there is a legitimate government interest in a rational basis to go forward the government's interest as expressed through this by a party and then you can come through that and then another party can come right back there's no there's no super presumption of the letter there's nothing that says ok we went through this process now it's stronger now it's just it's just subject to more and so you are splitting time with the government that's correct your honor and they are arguing that just the constitutionality question that's correct your and i'm presenting an argument for both a police here and i'm going to address the patentability issues this is a straightforward substantial evidence appeal even though the board me numerous factual findings based upon the prior art no legal challenges to patent ability instead it resists to narrow substantial evidence issues there's substantial evidence to support both of the findings that are challenges but the core only needs to address but but more importantly this is a factual finding here the board found as a fact matter of fact at appendix thirty three that a person of ordinary skill in the art would understand that a compound that inhibits vs arcee would inhibit  it found dr keeps testimony not persuasive and it credited included our expert testimony saying there are similarities between the s r c and c s r c such that a skilled artisan would but another reason why their argument fails is because the sign eve reference the signage reference says that you see a new one and the board made findings about this at appendix twenty nine and  at appendix twenty nine and at thirty three that the sign it a star thirty five or the board said that sign a discloses that use you know on inhibits multiple the human breast cancer cells and the board found as a matter of fact based upon this reference and based upon our experts testimony that a person or news can only art would understand that you see you know one is  and that's being applied to two cells right there so that's additional substantial evidence that supports the board's decision here in this case where they found arches experts testimony not persuasive that should resolve the appeal because there is no need to look to any other art when you have references that explain that you see in a one as it tires in kind is inhibitor and it doesn't and i think that it's important also to look to take a step back and look at the what the board did here in this case the board's rehearing decision which arch really wholly ignores rejected the very premise of march's argument that it depends inhibitor as well a lot of this art is showing that these compounds inhibit multiple different enzymes or proteins and that's all that's being shown here the board here had the evidence before it and made a determination on the facts based upon the significant evidence in the prior art and in our experts testimony that you see in a one is a tiresome kind of there's nothing in the five one two patent inhibitor now i just would also like to briefly touch upon the motivation argument that raises busy again that's another issue that the court does not need to reach because or and the board made a finding of that on its rehearing decision at forty three and forty four word says its decision doesn't depend upon any of the stores pouring are so given that that's enough right there to for the motivation argument if the court needed to reach the motivation to combine argument that's another factual finding that supported by substantial evidence where the board found arches evidence not persuasive it looked at the fact that our expert testified that you see a no one in stores for in have a similar mechanism of action they both inhibit kinases by interfering with a t p binding they both have similar effects on the cell cycle and they are structurally similar the board thank you herman please the court katherine on behalf of the united states we intervene to address the constitutional issues and i would just like to start out by responding to a couple points that the other side made first is that the due process question here is whether there any rational basis for congress decision to apply in our party's review to patents that issue prior to the a i a they agreed that it serves the purpose of weeding out the erroneous they granted patents that ins to the process question of cases that look to congressional purpose and i just want to point out that those citations are in the the due process portion of the opinion and there's no question that that there's no dispute that the due process question is whether congress had a rational basis for for this application of the statute so this is still good law on on that issue and we think it for closes that that the due process question here in addition we think that there's there is no takings problem because the cancellation of a patent through i p r rests on a determination by the agency that the patent holder never had a valid property interest and the patent determined that there was vote that the board agreed with the constitutional challenge yes it could have declined to institute in her party's review in this case so you think that that's something that needs to be writ prior to the to the agency's discretion and are point out that the supreme court in center basin and more recently in two thousand and twelve in elgin made clear that sometimes quoted statement that agencies don't have jurisdiction to consider constitutional issue than are you saying that the board does have the authority quite independent of its own of its right to decline to institute but it does have  authority to rule on a constitutional challenge to the statute or are you saying that well it can always decline and thereby avoiding the problem altogether will you and i think i mean it's clear that as you know congress but for the fact that we think that statute is unconstitutional and we think it's unconstitutional therefore we declined to institute is that it was awful act in your view in the view of the department of justice for the for the board to t would be unreviewable under quo so yes or no i do think that because that's committed to the agency discretion that if if the court if the agency found that there was a constitutional problem that would be under review well but of course you know the agency ha than the government is is professing it's not just those who had valid patents it's all patent holders are in the same regulatory disability of having to deal with say a cross eyed judicial additional divisional administrative process a process that has a lower bar to institution than the substantial new question about billing line that was drawn for examination and that also has the additional disability of having institution be granted when there is competing the congress decided that the clear and convincing evidence test in district court was really too onerous for patent challengers and decided to convert the test into one for by a they have to every day they're on the lines with the licensing decisions and those decisions infected by the fact that a large pharmaceutical company could store you into reason where i p r and have to go through a mid six figure challenge before you get to enforce because perhaps it's a one two punch the fact that one's not interfering with the other is a good thing whatever i cannot with thought that's what it said that was the state of the ark the inventors here believe that piracy in kindness